One focus.

Progressing product candidates targeting immune-mediated inflammatory diseases

pipeline Avalo

We are advancing a pipeline that emphasizes high-value, potentially best-in-class and best-in-disease biologics for immune-mediated inflammatory diseases. Our lead asset, abdakibart (AVTX-009), is a high affinity, highly potent humanized IgG monoclonal antibody (mAb) designed to specifically inhibit IL-1β and block downstream inflammatory pathways. Abdakibart (AVTX-009) is currently being studied as a treatment for hidradenitis suppurativa (HS). We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart.

Explore the scientific rationale behind targeting IL-1β

Abdakibart (AVTX-009): Potential best-in-class and best-in-disease profile in HS

Abdakibart (AVTX-009) is an investigational drug being studied as a potential treatment for HS. Because it inhibits IL-1β and blocks inflammatory pathways, abdakibart (AVTX-009) might help control chronic inflammation, nodule and abscess formation, and tissue damage often seen with HS.

Learn about HS and its underlying IL-1β dysregulation
The skin’s complex structure and pressurized environment can limit mAb distribution, often necessitating higher doses for effective target engagement in dermatological conditions such as HS.1,2 However, abdakibart (AVTX-009)’s high affinity, potency, and specificity for IL-1β may help overcome this barrier by enabling effective IL-1β inhibition even when tissue penetration is limited.

Abdakibart (AVTX-009) in HS3

Lotus logo

LOTUS was a global, randomized, double-blind Phase 2 trial of abdakibart (AVTX-009) in people with HS.

Discover the LOTUS Trial

References: 1. Ryman JT, Meibohm B. CPT Pharmacometrics Syst Pharmacol. 2017;6:576-588. 2. Witte-Handel E et al. J Invest Dermatol. 2019;139:1294-1305. 3. Bihorel S et al. AAPS J. 2014;16(5):1009-1017. 4. Clinicaltrials.gov. NCT06603077. Accessed November 26, 2024. https://clinicaltrials.gov/study/NCT06603077.

AVTX-010, a long-acting next-generation anti-IL-1β mAb

Less frequent dosing is an important driver of physician and patient preference in chronic inflammatory diseases, and we believe AVTX-010 may further strengthen our potential in HS, while creating opportunities to expand into additional indications where extended dosing intervals may improve treatment convenience, adherence, and overall patient experience.